Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | mitogen activated protein kinase kinase kinase | 0.0038 | 0.133 | 0.1388 |
Echinococcus multilocularis | kinase protein | 0.0038 | 0.133 | 0.1388 |
Echinococcus granulosus | 5'partial|3'partial|mitogen activated protein kinase kinase kinase | 0.0038 | 0.133 | 0.133 |
Echinococcus multilocularis | arachidonate 5 lipoxygenase | 0.0102 | 0.5419 | 0.5656 |
Onchocerca volvulus | 0.0017 | 0 | 0.5 | |
Echinococcus multilocularis | mitogen activated protein kinase kinase kinase | 0.0038 | 0.133 | 0.1388 |
Echinococcus granulosus | arachidonate 5 lipoxygenase | 0.0102 | 0.5419 | 0.5419 |
Schistosoma mansoni | lipoxygenase | 0.0102 | 0.5419 | 0.5419 |
Schistosoma mansoni | lipoxygenase | 0.0071 | 0.3461 | 0.3461 |
Echinococcus granulosus | mitogen activated protein kinase kinase kinase | 0.0039 | 0.1388 | 0.1388 |
Schistosoma mansoni | retinoic acid receptor RXR | 0.0173 | 1 | 1 |
Brugia malayi | Protein kinase domain containing protein | 0.0039 | 0.1388 | 1 |
Echinococcus multilocularis | mitogen activated protein kinase kinase kinase | 0.0038 | 0.133 | 0.1388 |
Plasmodium vivax | multidomain scavenger receptor, putative | 0.0017 | 0 | 0.5 |
Plasmodium falciparum | LCCL domain-containing protein | 0.0017 | 0 | 0.5 |
Echinococcus granulosus | 3'partial|mitogen activated protein kinase kinase kinase | 0.0038 | 0.133 | 0.133 |
Echinococcus multilocularis | kinase protein | 0.0038 | 0.133 | 0.1388 |
Loa Loa (eye worm) | TKL/MLK/TAK1 protein kinase | 0.0039 | 0.1388 | 1 |
Echinococcus multilocularis | retinoic acid receptor rxr beta a retinoic acid receptor rxr alpha a retinoic acid receptor rxr alpha | 0.0167 | 0.9582 | 1 |
Echinococcus multilocularis | mitogen activated protein kinase kinase kinase 7 | 0.0038 | 0.133 | 0.1388 |
Onchocerca volvulus | 0.0017 | 0 | 0.5 | |
Echinococcus multilocularis | mitogen activated protein kinase kinase kinase | 0.0039 | 0.1388 | 0.1449 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
ED25 (functional) | = 0.09 mg kg-1 day-1 | Effective dose to reduce 25% of glucose levels in blood | ChEMBL. | 1635060 |
ED25 (functional) | = 0.09 mg kg-1 day-1 | Effective dose to reduce 25% of glucose levels in blood | ChEMBL. | 1635060 |
ED25 (functional) | = 0.3 mg kg-1 day-1 | Effective dose to reduce 25% of triglyceride levels in plasma | ChEMBL. | 1635060 |
ED25 (functional) | = 0.3 mg kg-1 day-1 | Effective dose to reduce 25% of triglyceride levels in plasma | ChEMBL. | 1635060 |
Reduction (functional) | = 41 % | Maximum reduction in plasma triglyceride levels in KKA mice at a dosage of 0.001% in diet | ChEMBL. | 1635060 |
Reduction (functional) | = 41 % | Maximum reduction in plasma triglyceride levels in KKA mice at a dosage of 0.001% in diet | ChEMBL. | 1635060 |
Reduction (functional) | = 50 % | Maximum reduction in blood glucose levels in KKA mice at a dosage of 0.001% in diet | ChEMBL. | 1635060 |
Reduction (functional) | = 50 % | Maximum reduction in blood glucose levels in KKA mice at a dosage of 0.001% in diet | ChEMBL. | 1635060 |
Reduction (functional) | = 51 % | Maximum reduction in blood glucose levels in KKA mice at a dosage of 0.005% in diet | ChEMBL. | 1635060 |
Reduction (functional) | = 51 % | Maximum reduction in blood glucose levels in KKA mice at a dosage of 0.005% in diet | ChEMBL. | 1635060 |
Reduction (functional) | = 72 % | Maximum reduction in plasma triglyceride levels in KKA mice at a dosage of 0.005% in diet | ChEMBL. | 1635060 |
Reduction (functional) | = 72 % | Maximum reduction in plasma triglyceride levels in KKA mice at a dosage of 0.005% in diet | ChEMBL. | 1635060 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.